XSHG
600200
Market cap30mUSD
Dec 29, Last price
0.29CNY
Name
JiangSu WuZhong Pharmaceutical Development Co Ltd
Chart & Performance
P/E
2.92
P/S
0.13
EPS
0.10
Div Yield, %
—
Shrs. gr., 5y
-0.34%
Rev. gr., 5y
-5.40%
Revenues
1.60b
-28.64%
Net income
70m
P
CFO
-275m
L+34.85%
Dividend
Jun 15, 20180.056 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
JiangSu WuZhong Pharmaceutical Development Co., Ltd., along with its affiliated entities, operates as a diversified Chinese enterprise with interests spanning the pharmaceutical, real estate, and chemical industries. The company is actively involved in the research, production, and sale of a broad spectrum of pharmaceutical products. These include medications targeting infections, digestive ailments, cardiovascular and cerebrovascular conditions, viral diseases, vitamin deficiencies, and hemostasis. Its pharmaceutical offerings also encompass immunomodulators, featuring biopharmaceuticals, traditional chemical drugs, and contemporary Chinese medicines. These treatments are available in diverse formats, such as intravenous solutions, injectable powders and liquids, capsules, granular forms, tablets, emulsions, and oral liquid preparations. In its chemical division, the company focuses on the development, manufacturing, and distribution of various dyes and their intermediates. Additionally, its real estate arm undertakes the construction of both market-rate and subsidized residential properties. Founded in 1994, the company is based in Suzhou, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||